局部莫匹罗星减少新生儿重症监护病房婴儿金黄色葡萄球菌定植的随机安慰剂对照试验
该前瞻性双盲随机对照试验在三级NICU中纳入216例金黄色葡萄球菌定植婴儿,比较5天局部莫匹罗星与安慰剂(凡士林)的去定植效果。莫匹罗星组初始去定植成功率83%,显著高于对照组的20%(P < .001);虽然复发常见,但重复治疗仍更有效,且莫匹罗星组细菌无菌部位感染有减少趋势(2% vs 8%,P = .057)。
要点
- 局部莫匹罗星5天疗程可有效去定植,初始成功率83% vs 20%(P < .001)。
- 定植复发常见(73% vs 79%),但重复莫匹罗星治疗仍更有效(78% vs 10%)。
- ≤30周早产儿亚组结果相似(83% vs 18%),莫匹罗星组无侵袭性金黄色葡萄球菌感染。
核心结论
- 普遍主动监测联合局部莫匹罗星靶向治疗是NICU婴儿成功的去定植策略,可能预防金黄色葡萄球菌感染。
- 金黄色葡萄球菌定植常复发,需要重复治疗。
研究设计与样本
- 每周普遍主动监测采用聚合酶链反应筛查识别定植婴儿,定植婴儿接受5天莫匹罗星或凡士林疗程,筛查再次阳性者重复疗程。
- 共216例婴儿入组,205例纳入数据分析。
主要发现
- 莫匹罗星组初始去定植成功86/104(83%),对照组20/101(20%)(P < .001)。
- 复发定植常见:莫匹罗星组59/81(73%),对照组26/33(79%);后续去定植莫匹罗星组38/49(78%) vs 对照组2/21(10%)(P < .001)。
- 胎龄≤30周亚组去定植莫匹罗星组63/76(83%) vs 对照组13/74(18%)(P < .001)。
- 细菌无菌部位感染莫匹罗星组2/104(2%) vs 对照组8/101(8%)(P = .057)。
- 莫匹罗星组无侵袭性金黄色葡萄球菌感染,对照组感染中50%为金黄色葡萄球菌且1例死亡。
关键数值与推荐
- 莫匹罗星5天疗程用于金黄色葡萄球菌定植婴儿,筛查再次阳性者重复疗程。
临床怎么用
- 对NICU婴儿实施每周普遍主动监测,识别金黄色葡萄球菌定植者并给予局部莫匹罗星5天疗程去定植。
- 因定植常复发,需对筛查再次阳性者重复莫匹罗星治疗。
局限性
- 细菌无菌部位感染差异仅为趋势(P = .057),未达统计学显著性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of topical mupirocin in reducing Staphylococcus aureus colonization in infants in the neonatal intensive care unit (NICU). STUDY DESIGN: A prospective double-blind randomized controlled trial of mupirocin vs placebo in S aureus-colonized infants was conducted in a tertiary care NICU between October 2016 and December 2019. Weekly universal active surveillance with polymerase chain reaction screening identified colonized infants. Colonized infants received a 5-day course of mupirocin (mupirocin group) or petroleum jelly (control group). Repeat courses were given for additional positive screens. RESULTS: A total of 216 infants were enrolled; 205 were included in data analyses. Primary decolonization was more successful for mupirocin-treated infants (86 of 104 [83%]) than for controls (20 of 101; 20%) (P < .001). Although recurrent S aureus colonization occurred frequently (59 of 81 [73%] mupirocin-treated and 26 of 33 [79%] controls), subsequent decolonization remained more successful for mupirocin-treated infants than for controls (38 of 49 [78%] vs 2 of 21 [10%]; P < .001). Subgroup analyses of infants of ≤30 weeks' gestational age yielded similar results; decolonization occurred more often in mupirocin-treated infants compared with control infants (63 of 76 [83%] vs 13 of 74 [18%]; P < .001). Bacterial sterile site infections tended to be less frequent in mupirocin-treated infants compared with controls (2 of 104 [2%] vs 8 of 101 [8%]; P = .057). No invasive S aureus infections occurred in mupirocin-treated infants, but 50% of infections in controls were from S aureus, and 1 resulted in death. CONCLUSIONS: Universal active surveillance and targeted treatment with topical mupirocin is a successful decolonization strategy for NICU infants and may prevent S aureus infection. However, S aureus colonization frequently recurs, necessitating repeat treatment. TRIAL REGISTRATION: Clinicaltrials.gov: NCT02967432.
引用
- Nelson MU, Shaw J, Gross SJ, et al. Randomized Placebo-Controlled Trial of Topical Mupirocin to Reduce Staphylococcus aureus Colonization in Infants in the Neonatal Intensive Care Unit. J Pediatr. 2021. PMID: 34023342. doi:10.1016/j.jpeds.2021.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。